SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals filed a DEFA14A supplement to its definitive…

CATALYST PHARMACEUTICALS, INC. · DEFA14A filed Jun 30, 2026 at 17:22 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Jun 30, 2026 at 17:22 ET

Catalyst Pharmaceuticals filed a DEFA14A supplement to its definitive proxy statement for the July 8, 2026 special meeting to vote on the $31.50/share all-cash acquisition by Angelini Pharma. The supplement voluntarily adds disclosures regarding a shareholder lawsuit (Seaward v. Catalyst) alleging inadequate proxy disclosures, additional background on merger negotiations with multiple parties, and financial projections. The company believes the lawsuit is without merit and the supplemental disclosures aim to mitigate litigation risk.

  • Special meeting to vote on merger with Angelini Pharma scheduled for July 8, 2026; record date June 3, 2026.
  • One shareholder lawsuit filed June 10, 2026 in N.D. Illinois (Seaward v. Catalyst) alleging inadequate proxy disclosures; company believes claims are without merit.
  • Supplemental disclosures include December 2025 and March 2026 financial projections for FIRDAPSE, AGAMREE, and FYCOMPA revenue through 2035.
  • CEO Richard Daly proposed retention terms: $875,000 base salary, 80% annual bonus target, 2x base+target retention bonus (75% at year 1, 25% at year 2) with non-compete and waiver of Good Reason rights.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access